Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Leases (2019 - 2026)

Ocular Therapeutix has reported Current Leases over the past 8 years, most recently at $3.2 million for Q1 2026.

  • For Q1 2026, Current Leases rose 47.03% year-over-year to $3.2 million; the TTM value through Mar 2026 reached $3.2 million, up 47.03%, while the annual FY2025 figure was $2.8 million, 45.73% up from the prior year.
  • Current Leases for Q1 2026 was $3.2 million at Ocular Therapeutix, up from $2.8 million in the prior quarter.
  • Over five years, Current Leases peaked at $3.2 million in Q1 2026 and troughed at $1.5 million in Q1 2024.
  • A 5-year average of $2.0 million and a median of $1.8 million in 2022 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: decreased 15.18% in 2024 and later soared 60.86% in 2025.
  • Year by year, Current Leases stood at $1.6 million in 2022, then decreased by 0.81% to $1.6 million in 2023, then increased by 21.88% to $1.9 million in 2024, then surged by 45.73% to $2.8 million in 2025, then grew by 12.53% to $3.2 million in 2026.
  • Business Quant data shows Current Leases for OCUL at $3.2 million in Q1 2026, $2.8 million in Q4 2025, and $2.8 million in Q3 2025.